Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis

Salt Replacement for Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis

Adult cystic fibrosis (CF) patients admitted with an acute infection complicated by acid-base disturbance and decreased ventilation will be studied.

They will receive salt replacement to correct the acid-base disturbance and possibly their ventilation.

Assessment of symptoms (questionnaire), acid-base and electrolyte status (blood and urine tests) ventilation (overnight oxygen and carbon dioxide monitoring non-invasively) and sleep-wake pattern (actigraphy) will be carried out.

Study hypothesis: Acute volume and electrolyte replacement corrects hypochloremic hypovolemic metabolic alkalosis and compensatory hypoventilation/ hypercapnia in acute exacerbations of cystic fibrosis.

Study Overview

• Status: Unknown
• Conditions: Cystic Fibrosis
• Intervention / Treatment: Drug: Normal saline IV, salt tablets

Detailed Description

Background: Hypochloremic hypovolemic metabolic alkalosis contributes to hypercapnia in acute exacerbations of cystic fibrosis. Treatment of the metabolic alkalosis with volume and sodium chloride (NaCl) replacement could reduce hypoventilation and hypercapnia, thereby improving symptoms, sleep patterns and daytime activity level. This would avoid unnecessary treatment with non-invasive ventilation.

Hypothesis: Volume and NaCl replacement corrects hypochloremic hypovolemic metabolic alkalosis and compensatory hypoventilation/ hypercapnia in acute exacerbations of cystic fibrosis and results in symptomatic improvement.

Entry criteria:

• Adult cystic fibrosis patient
• Admission with acute exacerbation
• PaCO2 > 45 mmHg
• Primary metabolic alkalosis (acid-base diagram of Stinebaugh and Austin)
• Serum chloride (Cl) ≤ 98 mmol/L
• Serum albumin (alb) > 25 mmol/L

Intervention:

• Normal saline intravenously day(D)1,2,3. (Replace greater of Cl deficiency or acute weight loss, with 2/3 on D1 and remainder D2, D3)
• NaCl tablets 3 tds D4 to 10 (calculated to replace 7 mmol NaCl loss in 60 kg subject)

Random allocation to either:

1. Intervention + standard care (including standard dietary advice) D1-10
2. Standard care alone (including standard dietary advice) D1-10

Primary outcome measures: (D1, D4, D10)

• PaCO2 (performed at same time of day as admission ABG's)
• Acid-base status (Stinebaugh and Austin, ABG's)
• Serum chloride
• Overnight oximetry (% night SpO2<90%) and PtcCO2 (rise in CO2 overnight)

Secondary outcome measures: (D1, D4, D10)

• Serum albumin, sodium
• Body mass index (BMI)
• Spirometry (D1, D10)
• Headache scale
• Epworth sleepiness scale
• Wrist actigraphy (circadian rhythm and daytime activity level)(D1-10)
• Urinary chloride, potassium, sodium, pH, osmolality
• Baseline ABG's as stable outpatient (within 3 months, pre or post admission)

• Study Type: Interventional
• Enrollment: 40
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• Australia
  • Victoria
    • Melbourne, Victoria, Australia, 3181
      • Recruiting
      • The Alfred
      • Contact: Alan C Young, MBBS; Phone Number: pager 4576 613 9276 2000; Email: alan.young@med.monash.edu.au
      • Sub-Investigator: Alan C Young, MBBS

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adult cystic fibrosis patient
• Admission with acute exacerbation (criteria- fall in FEV1 > 10% from best in last 12/12, change in sputum volume and colour, new pulmonary infiltrate)
• PaCO2 > 45 mmHg on admission
• Primary metabolic alkalosis (acid-base diagram of Stinebaugh and Austin)
• Serum chloride (Cl) ≤ 98 mmol/L
• Serum albumin (alb) ≤ 25 mmol/L

Exclusion Criteria:

Concurrent diuretic therapy Concurrent glucocorticoid therapy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Primary outcome measures: (Day1, D4, D10)
•PaCO2 (performed at same time of day as admission ABG's)
•Acid-base status (Stinebaugh and Austin, ABG's)
•Serum chloride
•Overnight oximetry (% night SpO2<90%) and PtcCO2 (rise in CO2 overnight)

Secondary Outcome Measures

Outcome Measure
Secondary outcome measures: (Day1, D4, D10)
•Serum albumin, sodium
•Body mass index (BMI)
•Spirometry (D1, D10)
•Headache scale
•Epworth sleepiness scale
•Wrist actigraphy (circadian rhythm and daytime activity level)(D1-10)
•Urinary chloride, potassium, sodium, pH, osmolality
•Baseline ABG's as stable outpatient (within 3 months, pre or post admission)

Collaborators and Investigators

• Sponsor: Bayside Health
• Collaborators: National Health and Medical Research Council, Australia; Monash University; Cystic Fibrosis Federation Australia
• Investigators: Principal Investigator: Matthew T Naughton, MBBS, MD, The Alfred

Study record dates

Study Major Dates

• Study Start: February 1, 2004
• Study Completion: February 1, 2006

Study Registration Dates

• First Submitted: September 12, 2005
• First Submitted That Met QC Criteria: September 12, 2005
• First Posted (Estimate): September 14, 2005

Study Record Updates

• Last Update Posted (Estimate): September 14, 2005
• Last Update Submitted That Met QC Criteria: September 12, 2005
• Last Verified: September 1, 2005

More Information

Terms related to this study

• Keywords: Cystic fibrosis; Hypercapnia; Metabolic alkalosis; Salt replacement
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Metabolic Diseases; Respiratory Tract Diseases; Lung Diseases; Infant, Newborn, Diseases; Genetic Diseases, Inborn; Pancreatic Diseases; Acid-Base Imbalance; Fibrosis; Cystic Fibrosis; Alkalosis
• Other Study ID Numbers: 14/04